For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Dabigatran etexilate is used to prevent strokes in those with atrial fibrillation not caused by heart valve issues, as well as deep vein thrombosis and pulmonary embolism in persons with parenteral anticoagulant and to prevent deep vein thrombosis and pulmonary embolism in some circumstances.
The Dabigatran Etexilate market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028.
This report elaborates the market size, market characteristics, and market growth of the Dabigatran Etexilate industry, and breaks down according to the type, application, and consumption area of Dabigatran Etexilate. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and describes the leading companies.
In Chapter 2.3 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk assessment and industry recommendations were made for Dabigatran Etexilate in a special period. This chapter also compares the markets of Pre COVID-19 and Post COVID-19.
Chapter 2.5 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 6-10 consider the impact of COVID-19 on the regional economy.
Key players in the global Dabigatran Etexilate market covered in Chapter 11:
Bristol-Myers Squibb Company (US)
GlaxoSmithKline Plc. (UK)
Boehringer Ingelheim (Germany)
Mitsubishi Tanabe Pharma Corporation (Japan)
Sanofi S.A. (France)
Bayer Healthcare AG (Germany)
Aspen Holdings (South Africa)
Teva Pharmaceutical Industries Ltd. (Israel)
Abbott India Limited (India)
Pfizer, Inc. (US)
Eisai Inc. (US)
In Chapter 3, on the basis of types, the Dabigatran Etexilate market from 2018 to 2028 is primarily split into:
110mg capsules
150mg capsules
Others
In Chapter 4, on the basis of applications, the Dabigatran Etexilate market from 2018 to 2028 covers:
Clinical
Hospital
Personal
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2028) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10:
North America (Covered in Chapter 6)
United States
Canada
Mexico
Europe (Covered in Chapter 7)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8)
China
Japan
South Korea
Australia
India
Middle East and Africa (Covered in Chapter 9)
Saudi Arabia
UAE
Egypt
South Africa
South America (Covered in Chapter 10)
Brazil
Argentina
Columbia
Years considered for this report:
Historical Years: 2018-2022
Base Year: 2022
Estimated Year: 2023
Forecast Period: 2023-2028